Evidence map›Paper›PMID 26526764›Full record

ArticleFree radical biology & medicine2016

Role of NOS2 in pulmonary injury and repair in response to bleomycin.

Changjiang Guo, Elena Atochina-Vasserman, Helen Abramova, Blessy George, Veleeparambil Manoj, Pamela Scott, Andrew Gow

Open access · greenAbstract read
In one paragraph

Article in Free radical biology & medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 38 citations in OpenAlex.

  1. The inhibitory effects ofFood science and biotechnology · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Deficiency of the novel high mobility group protein HMGXB4 protects against systemic inflammation-induced endotoxemia in mice.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Surfactant protein-D modulation of pulmonary macrophage phenotype is controlled byAmerican journal of physiology. Lung cellular and molecular physiology · 2019
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Protective Role of Surfactant Protein-D Against Lung Injury and Oxidative Stress Induced by Nitrogen Mustard.Toxicological sciences : an official journal of the Society of Toxicology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Changjiang GuoDepartment of Pharmacology & Toxicology, Rutgers, the State University of New Jersey, Piscataway, NJ, USA.
Elena Atochina-VassermanDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Helen AbramovaDepartment of Pharmacology & Toxicology, Rutgers, the State University of New Jersey, Piscataway, NJ, USA.
Blessy GeorgeDepartment of Pharmacology & Toxicology, Rutgers, the State University of New Jersey, Piscataway, NJ, USA.
Veleeparambil ManojDepartment of Molecular Genetics, Cleveland Clinic, Lerner Research Institute, Cleveland, OH, USA.
Pamela ScottDepartment of Pharmacology & Toxicology, Rutgers, the State University of New Jersey, Piscataway, NJ, USA.
Andrew GowDepartment of Pharmacology & Toxicology, Rutgers, the State University of New Jersey, Piscataway, NJ, USA. Electronic address: gow@rci.rutgers.edu.
Rutgers, The State University of New Jersey · USCleveland Clinic Lerner College of Medicine · USUniversity of Pennsylvania · US

Funding

NO-Modified Biomolecules and Pulmonary SignalingR01HL086621 · NHLBI · RUTGERS, THE STATE UNIV OF N.J. · PI GOW, ANDREW J · 2008 to 2016
$2.8M
NHLBI NIH HHS R01 HL086621PHS HHS NIEHS P30E5S005022PHS HHS NIHHL086621
6 · The paper itself

Abstract

Nitric oxide (NO) is derived from multiple isoforms of the Nitric Oxide Synthases (NOSs) within the lung for a variety of functions; however, NOS2-derived nitrogen oxides seem to play an important role in inflammatory regulation. In this study, we investigate the role of NOS2 in pulmonary inflammation/fibrosis in response to intratracheal bleomycin instillation (ITB) and to determine if these effects are related to macrophage phenotype. Systemic NOS2 inhibition was achieved by administration of 1400W, a specific and potent NOS2 inhibitor, via osmotic pump starting six days prior to ITB. 1400W administration attenuated lung inflammation, decreased chemotactic activity of the broncheoalveolar lavage (BAL), and reduced BAL cell count and nitrogen oxide production. S-nitrosylated SP-D (SNO-SP-D), which has a pro-inflammatory function, was formed in response to ITB; but this formation, as well as structural disruption of SP-D, was inhibited by 1400W. mRNA levels of IL-1β, CCL2 and Ptgs2 were decreased by 1400W treatment. In contrast, expression of genes associated with alternate macrophage activation and fibrosis Fizz1, TGF-β and Ym-1 was not changed by 1400W. Similar to the effects of 1400W, NOS2-/- mice displayed an attenuated inflammatory response to ITB (day 3 and day 8 post-instillation). The DNA-binding activity of NF-κB was attenuated in NOS2-/- mice; in addition, expression of alternate activation genes (Fizz1, Ym-1, Gal3, Arg1) was increased. This shift towards an increase in alternate activation was confirmed by western blot for Fizz-1 and Gal-3 that show persistent up-regulation 15 days after ITB. In contrast arginase, which is increased in expression at 8 days post ITB in NOS2-/-, resolves by day 15. These data suggest that NOS2, while critical to the development of the acute inflammatory response to injury, is also necessary to control the late phase response to ITB.

Indexed as

AnimalsBleomycinLipopolysaccharidesLungLung InjuryMacrophage ActivationMice, Inbred C57BLNitric Oxide Synthase Type IIRegenerationTranscriptomeBleomycinLipopolysaccharidesNitric Oxide Synthase Type IINos2 protein, mouseBleomycinNOS2 inhibitorPulmonary inflammationS-nitrosylationSurfactant protein-D

Identifiers

PMID26526764
PMCPMC5059840
OpenAlexW2191792742

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.